NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
Clinical Trials
9 trialsNCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00711412 2018-07-18
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Northwestern University
Phase 2 Completed
NCT00848783 2018-01-08
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Phase 2 Terminated
NCT00176800 2016-08-22
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00319735 2016-04-28
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00525915 2015-02-09
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed